-
Mashup Score: 21Dynamics of Immune Reconstitution and Impact on Outcomes Across CAR-T Cell Products in Large B-Cell Lymphoma - 7 day(s) ago
Abstract. Patients treated with chimeric antigen receptor T-cell (CAR-T) therapy are subject to profound immune suppression. Dynamics of immune reconstitution (IR) and impacts of IR on outcomes following infusion across CAR-T products are not well understood. Here, we profiled IR in 263 patients with relapsed/refractory large B-cell lymphoma receiving CAR-T therapy (axicabtagene ciloleucel 44.9%, lisocabtagene maraleucel 30.4%, tisagenlecleucel 24.7%). Following infusion, patients remain persistently immunosuppressed, with 48.1% having CD4+ T cell counts <200/µL and median CD3-19+ B cell counts remaining zero through 1 year after CAR-T. IR differences exist by product, with fastest CD4+ T cell recovery seen for tisagenlecleucel, driven primarily by more rapid recovery of the CD4+CCR7-45RA- effector memory subset. Natural killer cell, but not CD4+ T cell, recovery is significantly associated with favorable progression-free (HR: 0.647; 95% CI: 0.476-0.880) and overall survival (HR: 0.637
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8
As the number of recipients of chimeric antigen receptor (CAR) T-cell therapies has rapidly increased, sporadic reports of T-cell lymphomas arising de novo
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities https://t.co/UrKaHjDus1
-
-
Mashup Score: 19Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma - 11 day(s) ago
Key PointsA lower circulating lymphocyte-to-monocyte ratio and proportion of B cells at apheresis predict a reduced likelihood of response to CAR-T.On expl
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma https://t.co/cUSP8Ppr0E
-
-
Mashup Score: 2
Severe hemophilia A is managed with factor VIII replacement or hemostatic products that stop or prevent bleeding. Data on gene therapy with hematopoietic stem-cell (HSC)–based expression of factor …
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A | New England Journal of Medicine https://t.co/MFaDJ0giEE
-
-
Mashup Score: 10
Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma | New England Journal of Medicine https://t.co/8LytRpPtLE
-
-
Mashup Score: 1Elías Campo: "El coneixement generat durant vint anys de recerca al projecte del genoma de la leucèmia comença a arribar al pacient" - 16 day(s) ago
Director de l’IDIBAPS i catedràtic de la UB
Source: www.ara.catCategories: General Medicine News, Hem/OncsTweet-
https://t.co/uqe1KNBt81
-
-
Mashup Score: 35CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML - 25 day(s) ago
Key Points. CD70 targeted CAR-T cells secreting a CD33 T-cell engaging antibody molecule eradicate CD33 or CD70 deficient AML
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML https://t.co/6S2iUd0xwc
-
-
Mashup Score: 34
Obecabtagene autoleucel (obe-cel) is an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy which uses an intermediate-affinity CAR to reduce toxic effects and improve persis…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia | New England Journal of Medicine https://t.co/cIR8LJQ3UH
-
-
Mashup Score: 18
Program: Late-breaking Abstracts Session: Late-Breaking Abstracts Session Hematology Disease Topics & Pathways: Research, Clinical trials, Lymphomas, Non-Hodgkin lymphoma, Clinical Research, B Cell lymphoma, Diseases, Lymphoid Malignancies 1 Medica l College of Wisconsin, Milwaukee, WI 2 Dana-Farber Cancer Institute / ECOG-ACRIN Biostatistics, Bostin, MA 3 Fred Hutchinson Cancer Center, University of Washington, Seattle, WA 4 Emory University / Winship Cancer Institute, Atlanta, GA 5 University of
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Stop ASCT for MCL...another evidence https://t.co/MyUi5Xj692
-
-
Mashup Score: 18
Program: Late-breaking Abstracts Session: Late-Breaking Abstracts Session Hematology Disease Topics & Pathways: Research, Clinical trials, Lymphomas, Non-Hodgkin lymphoma, Clinical Research, B Cell lymphoma, Diseases, Lymphoid Malignancies 1 Medica l College of Wisconsin, Milwaukee, WI 2 Dana-Farber Cancer Institute / ECOG-ACRIN Biostatistics, Bostin, MA 3 Fred Hutchinson Cancer Center, University of Washington, Seattle, WA 4 Emory University / Winship Cancer Institute, Atlanta, GA 5 University of
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Stop ASCT for MCL...another evidence https://t.co/MyUi5Xj692
-
Dynamics of Immune Reconstitution and Impact on Outcomes Across CAR-T Cell Products in Large B-Cell Lymphoma https://t.co/T7nngYI5wM